122 filings
Page 5 of 7
8-K
l7cg8e
22 Feb 22
Adagio Therapeutics Announces CEO Succession Plan
7:57am
8-K
5oecm 89kos0w9h84cer
18 Feb 22
Departure of Directors or Certain Officers
5:29pm
8-K
b3ocvedz
13 Jan 22
Regulation FD Disclosure
8:01am
8-K
zgo41 9wjleimg
14 Dec 21
Adagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against Omicron SARS-CoV-2 Variant
9:10am
8-K
i12ua
29 Nov 21
Regulation FD Disclosure
8:23am
8-K
hq9bwj3 xy
22 Nov 21
Adagio Therapeutics Announces Expansion of Management Team and Board of Directors
5:04pm
8-K
cbcer3
16 Nov 21
Regulation FD Disclosure
5:24pm
8-K
rfddimrtd8ohu qqpgev
15 Nov 21
Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results
8:08am
8-K
p7a4q2wlzhq3ywtutw
19 Oct 21
Adagio Therapeutics Announces New In Vitro Data Highlighting Broad and Potent Neutralization of ADG20 Against All Known SARS-CoV-2 Variants
4:03pm
8-K
48vme
29 Sep 21
Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19
4:41pm
10-Q
hm444nr5aj76d pr8jqm
20 Sep 21
Quarterly report
4:17pm
8-K
ytdb0gcv9tefxm
20 Sep 21
Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business
4:05pm
8-K
dzm ffdh3t
10 Sep 21
Adagio Therapeutics Announces Expansion of Patient Population in Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19
7:55am
S-8
pl6bkk
23 Aug 21
Registration of securities for employees
4:35pm
SEC STAFF
ufcxvp
13 Aug 21
SEC staff action: Order
12:00am
8-K
zinclh
10 Aug 21
Amendments to Articles of Incorporation or Bylaws
5:26pm
424B4
qs05o2xpda
6 Aug 21
Prospectus supplement with pricing info
4:54pm
EFFECT
d7fe60i
6 Aug 21
Notice of effectiveness
12:15am
S-1MEF
otxlnep3zy92
5 Aug 21
Registration of additional securities for an S-1
9:20pm